Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
KADCYLA vs CLADRIBINE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.
Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.
Adjuvant treatment of patients with HER2-positive early breast cancer who have residual invasive disease after neoadjuvant taxane and trastuzumab-based treatment,Treatment of patients with HER2-positive metastatic breast cancer who previously received trastuzumab and a taxane, separately or in combination,Off-label: Use in HER2-positive advanced gastric cancer (limited data)
FDA-approved: Treatment of hairy cell leukemia.,Off-label: Chronic lymphocytic leukemia (CLL), multiple sclerosis (relapsing forms), Waldenström macroglobulinemia, cutaneous T-cell lymphoma, and as part of conditioning regimens for hematopoietic stem cell transplantation.
3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).
Terminal half-life approximately 4 days (range 2.8-5.6 days), supporting every-3-week dosing.
Terminal elimination half-life is approximately 5.4 hours (range 4.6–6.7 hours) after intravenous administration; prolonged in renal impairment.
DM1 is primarily metabolized by CYP3A4 and to a lesser extent by CYP3A5.
Cladribine is primarily metabolized intracellularly by deoxycytidine kinase to its active triphosphate. It is also phosphorylated by deoxyguanosine kinase in mitochondria. Catabolism involves deamination by adenosine deaminase (ADA) to 2-chloroadenine, which is further metabolized.
Primarily hepatic metabolism with biliary excretion; minimal renal elimination (<10% unchanged).
Renal (approximately 50% as unchanged drug); fecal elimination is minimal (<5%).
93% bound to plasma proteins (trastuzumab component).
Approximately 20–30% bound to plasma proteins.
Approximately 2.58 L/m² (central Vd), indicating limited extravascular distribution.
Approximately 4.5 L/kg (range 2.3–9.6 L/kg), indicating extensive tissue distribution.
100% (intravenous administration only).
Oral: approximately 37–55% (first-pass metabolism); subcutaneous: approximately 100%.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥30 m L/min). Safety and efficacy not established in severe renal impairment (Cr Cl <30 m L/min).
GFR <50 m L/min: reduce dose by 50%; GFR <10 m L/min: avoid use.
No dose adjustment for mild hepatic impairment (Child-Pugh A). Not recommended for moderate (Child-Pugh B) or severe (Child-Pugh C) hepatic impairment due to lack of data.
Child-Pugh Class B: reduce dose by 50%; Child-Pugh Class C: contraindicated.
Safety and efficacy in pediatric patients have not been established.
0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course). No specific pediatric dose adjustments beyond weight-based dosing.
No specific dose adjustment recommended for elderly patients. Clinical studies included patients aged ≥65 years, but no overall differences in safety or efficacy were observed.
No specific dose adjustment recommended; monitor renal function and adjust accordingly.
WARNING: HEPATOTOXICITY, CARDIAC TOXICITY, EMBRYO-FETAL TOXICITY Hepatotoxicity: Severe hepatotoxicity has been observed, including liver failure and death. Monitor liver function tests prior to each dose and as clinically indicated. Cardiac Toxicity: Left ventricular ejection fraction (LVEF) should be assessed prior to initiation and at regular intervals during treatment. Discontinue for clinically significant decline. Embryo-Fetal Toxicity: Exposure during pregnancy can cause embryo-fetal harm. Advise patients of these risks and need for effective contraception.
WARNING: Neurotoxicity and Hematologic Toxicity. Cladribine can cause severe bone marrow suppression (neutropenia, anemia, thrombocytopenia) and neurotoxicity (including paralysis, coma, and death). Dose-dependent and more frequent in high doses.
Hepatotoxicity: Monitor liver function tests; dose reduction or discontinuation may be required for elevated liver enzymes or bilirubin.,Cardiac toxicity: Assess LVEF before and during treatment; discontinue if symptomatic heart failure or significant asymptomatic decline.,Pulmonary toxicity: Interstitial lung disease (ILD) including pneumonitis has been reported; monitor for signs/symptoms and discontinue if confirmed.,Extravasation: Administer as IV infusion; extravasation may cause tissue necrosis. Ensure proper IV access.,Thrombocytopenia: Monitor platelet counts; dose modifications required for grade 3 or 4 thrombocytopenia.,Neuropathy: Peripheral neuropathy may occur; monitor and manage accordingly.,Embryo-fetal toxicity: Advise of risk and use effective contraception during and 7 months after treatment.,Increased intracranial pressure: Cases of reversible posterior leukoencephalopathy syndrome (RPLS) reported; monitor and discontinue if occurs.
Myelosuppression: Monitor blood counts regularly; dose adjustment or discontinuation may be needed.,Neurotoxicity: Risk increased with high doses and in patients with renal impairment.,Nephrotoxicity: Use with caution in renal impairment; reduce dose if Cr Cl < 60 m L/min.,Hepatotoxicity: Monitor liver function tests.,Secondary malignancies: Increased risk of myelodysplasia and acute myeloid leukemia.,Infections: Increased susceptibility due to lymphopenia; consider prophylaxis.
Known hypersensitivity to ado-trastuzumab emtansine or any of its components,Pregnancy (can cause embryo-fetal harm)
Hypersensitivity to cladribine or any component of the formulation.,Pre-existing severe bone marrow suppression (e.g., neutropenia, thrombocytopenia) unless due to underlying disease.,Pregnancy: Can cause fetal harm.,Lactation: Discontinue nursing or drug.
No specific food interactions are known for Kadcyla. However, avoid grapefruit and grapefruit juice as they may inhibit CYP3A4 and potentially increase exposure. Maintain a healthy diet to manage nausea and support overall health.
No significant food interactions. Avoid grapefruit juice due to potential CYP3A4 interaction (though minimal). Maintain adequate hydration to prevent tumor lysis syndrome in hematologic malignancies.
Kadcyla (ado-trastuzumab emtansine) is an antibody-drug conjugate. Trastuzumab component can cause oligohydramnios, fetal renal impairment, and pulmonary hypoplasia when administered during the second and third trimesters. The DM1 component (emtansine) is a microtubule inhibitor with potential embryofetal toxicity. Based on its mechanism and animal studies, there is risk for teratogenicity in the first trimester, including structural anomalies. Avoid use during pregnancy unless benefit outweighs risk; advise effective contraception.
FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third trimesters: Risk of fetal myelosuppression, intrauterine growth restriction, and preterm labor. Cladribine crosses the placenta and may cause fetal hematopoietic suppression.
It is not known whether Kadcyla is excreted in human milk. Due to the potential for serious adverse reactions in nursing infants, including tumorigenicity and developmental toxicity, advise women not to breastfeed during treatment and for at least 7 months after the last dose. M/P ratio is unknown.
Contraindicated during breastfeeding. Cladribine is excreted into human milk; M/P ratio not determined. Potential for severe adverse effects in nursing infants, including myelosuppression and immunosuppression. Discontinue breastfeeding during therapy and for at least 7 days after last dose.
No dose adjustment recommendations specific to pregnancy; however, pharmacokinetics may be altered due to increased plasma volume and renal clearance. Use only if clearly needed. Consider therapeutic drug monitoring if available, but no established target levels. Close maternal-fetal monitoring recommended.
No established dose adjustments in pregnancy. Use is contraindicated. If unavoidable, lowest effective dose and close monitoring for maternal and fetal toxicity. Pharmacokinetic changes in pregnancy (increased volume of distribution, renal clearance) may reduce exposure; however, risks outweigh benefits.
Monitor left ventricular ejection fraction (LVEF) before and during treatment due to risk of cardiotoxicity. Infusion reactions are common; premedicate with antihistamines and corticosteroids. Do not substitute trastuzumab emtansine for trastuzumab or ado-trastuzumab emtansine. Avoid concomitant use with strong CYP3A4 inhibitors or inducers. Monitor for hepatotoxicity and pulmonary toxicity. Dose reduction required for thrombocytopenia or elevated transaminases.
Cladribine is a purine nucleoside analog that causes lymphocyte depletion, effective in hairy cell leukemia and multiple sclerosis. Monitor for severe lymphopenia, opportunistic infections (e.g., herpes zoster, tuberculosis), and delayed myelosuppression. Do not administer live vaccines during or after treatment. Due to high bioavailability after subcutaneous administration, adjust dose for renal impairment. Hypersensitivity reactions may occur; premedicate with antihistamines if needed.
This drug is given as an IV infusion every 3 weeks. It may cause infusion reactions during or shortly after administration; tell your doctor immediately if you experience chills, fever, difficulty breathing, or chest pain.,Kadcyla can cause heart problems; you will have regular heart function tests (echocardiograms) before and during treatment. Report any new shortness of breath, cough, or swelling of ankles/legs.,This medication can cause liver damage; blood tests will be done to monitor liver function. Notify your doctor if you develop yellowing of skin/eyes, dark urine, or abdominal pain.,Kadcyla may lower platelet counts, increasing bleeding risk. Avoid activities that may cause injury or bruising. Report unusual bleeding or bruising.,This drug can cause severe birth defects; use effective contraception during treatment and for at least 7 months after the last dose. Do not breastfeed while taking Kadcyla.,You may experience fatigue, nausea, muscle/joint pain, or headache. Report persistent or severe symptoms to your healthcare provider.
Cladribine can significantly lower your white blood cell count, increasing infection risk. Report fever, chills, or sore throat immediately.,Avoid live vaccines (e.g., MMR, shingles) during and for at least 6 months after treatment.,You may experience fatigue, nausea, headache, or skin reactions at injection site. These are common but report severe symptoms.,Use effective contraception during treatment and for at least 6 months after the last dose. Cladribine may harm a fetus.,You will need regular blood tests to monitor your blood cell counts, liver, and kidney function.
No interactions on record
"The combination of cabazitaxel and cladribine may potentiate myelosuppression due to overlapping bone marrow toxicity profiles. Cabazitaxel, a taxane antineoplastic, inhibits microtubule disassembly, while cladribine, a purine analog, incorporates into DNA and induces apoptosis in dividing and resting lymphocytes. Concurrent use increases the risk of severe neutropenia, thrombocytopenia, and anemia, potentially leading to febrile neutropenia or bleeding complications."
"Cladribine, a purine nucleoside analog with potent immunosuppressive properties, may reduce the pharmacodynamic effects of cardiac glycosides such as acetyldigitoxin. This interaction is hypothesized to occur through cladribine-induced modulation of myocardial cellular signaling pathways that decrease sensitivity to digitalis compounds, potentially leading to reduced inotropic efficacy. Clinically, this could manifest as diminished control of heart rate in patients with atrial fibrillation or worsening heart failure symptoms, particularly in those relying on acetyldigitoxin for rate control or inotropic support."
"The risk or severity of adverse effects can be increased when Pimecrolimus is combined with Cladribine."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about KADCYLA vs CLADRIBINE, answered by our medical review team.
KADCYLA is a Antineoplastic Agent that works by KADCYLA (ado-trastuzumab emtansine) is an antibody-drug conjugate composed of trastuzumab, a humanized anti-HER2 antibody, linked to the microtubule inhibitor DM1 (maytansinoid). It binds to HER2 receptors on tumor cells, internalized via receptor-mediated endocytosis, and releases DM1 intracellularly, causing cell cycle arrest and apoptosis.. CLADRIBINE is a Antineoplastic Agent that works by Cladribine is a purine nucleoside analog that is phosphorylated intracellularly to its active triphosphate form, which inhibits DNA synthesis and repair, leading to cell death, particularly in lymphocytes. It also depletes adenosine deaminase (ADA) and accumulates in cells with high deoxycytidine kinase activity.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between KADCYLA and CLADRIBINE depend on the specific clinical indication. These are both Antineoplastic Agent agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of KADCYLA is: 3.6 mg/kg intravenously every 3 weeks until disease progression or unacceptable toxicity.. The standard adult dose of CLADRIBINE is: 0.09 mg/kg/day IV over 2 hours for 7 consecutive days; or 0.14 mg/kg/day IV over 2 hours for 5 consecutive days (total dose 0.7 mg/kg per course).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between KADCYLA and CLADRIBINE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. KADCYLA is classified as Category C. Kadcyla (ado-trastuzumab emtansine) is an antibody-drug conjugate. Trastuzumab component can cause oligohydramnios, fetal renal impairment, and pulmonary hypoplasia when administer. CLADRIBINE is classified as Category C. FDA Pregnancy Category D. First trimester: Avoid due to known teratogenicity in animal studies (skeletal and visceral malformations) and potential for MDS and AML. Second and third. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.